Squarepoint Ops LLC Sells 163,227 Shares of Emergent BioSolutions Inc. (NYSE:EBS)

Squarepoint Ops LLC trimmed its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 77.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 47,218 shares of the biopharmaceutical company's stock after selling 163,227 shares during the quarter. Squarepoint Ops LLC owned 0.09% of Emergent BioSolutions worth $451,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the stock. New York State Common Retirement Fund lifted its position in shares of Emergent BioSolutions by 41.7% during the 4th quarter. New York State Common Retirement Fund now owns 306,286 shares of the biopharmaceutical company's stock worth $2,928,000 after buying an additional 90,113 shares during the period. Bank of America Corp DE increased its position in shares of Emergent BioSolutions by 4.4% during the 4th quarter. Bank of America Corp DE now owns 332,099 shares of the biopharmaceutical company's stock worth $3,175,000 after purchasing an additional 14,054 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company's stock worth $14,722,000 after buying an additional 638,995 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Emergent BioSolutions in the 4th quarter valued at $1,831,000. Finally, Barclays PLC raised its holdings in shares of Emergent BioSolutions by 140.5% in the fourth quarter. Barclays PLC now owns 94,523 shares of the biopharmaceutical company's stock valued at $904,000 after buying an additional 55,215 shares during the last quarter. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on EBS. HC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Emergent BioSolutions in a research report on Tuesday, April 1st. Wall Street Zen cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Trading Up 9.8%

Shares of EBS stock traded up $0.59 on Friday, reaching $6.64. 914,650 shares of the stock were exchanged, compared to its average volume of 1,802,292. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. Emergent BioSolutions Inc. has a one year low of $4.02 and a one year high of $15.10. The stock has a market cap of $360.41 million, a PE ratio of -1.62 and a beta of 2.10. The stock has a 50 day moving average price of $5.46 and a 200 day moving average price of $7.45.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.22. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The firm had revenue of $222.20 million during the quarter, compared to analysts' expectations of $218.50 million. Equities research analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions announced that its Board of Directors has authorized a share repurchase plan on Monday, March 31st that permits the company to repurchase $50.00 million in outstanding shares. This repurchase authorization permits the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company's board of directors believes its stock is undervalued.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Keith Katkin sold 7,844 shares of the stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $6.30, for a total value of $49,417.20. Following the transaction, the director now owns 86,431 shares of the company's stock, valued at approximately $544,515.30. This represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72% decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.